Frances R Henshaw1,2, Lauren S Dewsbury3, Chai K Lim4, Genevieve Z Steiner2,3. 1. School of Health Science, Western Sydney University, Penrith, Australia. 2. Translational Health Research Institute (THRI), Western Sydney University, Penrith, Australia. 3. NICM Health Research Institute, Western Sydney University, Penrith, Australia. 4. Department of Biomedical Sciences, Faculty of Medicine, Health, and Human Sciences, Macquarie University, Macquarie Park, Australia.
Abstract
Introduction: Some cannabinoids have been identified as anti-inflammatory agents; however, their potential therapeutic or prophylactic applications remain controversial. The aim of this systematic review was to provide a timely and comprehensive insight into cannabinoid-mediated pro- and anti-inflammatory cytokine responses in preclinical in vivo studies. Methods and Materials: A systematic search was conducted using PubMed, Web of Science, EMBASE, and Scopus. Eligible studies where cannabinoids had been evaluated for their effect on inflammation in animal models were included in the analysis. Data were extracted from 26 of 4247 eligible full text articles, and risk of bias was assessed using the SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) tool. Studies examined cannabidiol (CBD; n=20); cannabigerol (CBG; n=1); delta 9-tetrahydrocannabinol (THC; n=2); THC and CBD separately (n=1); and THC and CBD in combination (n=2). Results: Tumor necrosis factor alpha, interleukin (IL)-1β, IL-6, and interferon gamma were the most commonly studied pro-inflammatory cytokines and their levels were consistently reduced after treatment with CBD, CBG, or CBD+THC, but not with THC alone. The association between cannabinoid-induced anti-inflammatory response and disease severity was examined. In 22 studies where CBD, CBG, or CBD in combination with THC were administered, a reduction in the levels of at least one inflammatory cytokine was observed, and in 24 studies, some improvements in disease or disability were apparent. THC alone did not reduce pro-inflammatory cytokine levels (n=3), but resulted in improvements in neuropathic pain in one study. Conclusions: This review shows that CBD, CBG, and CBD+THC combination exert a predominantly anti-inflammatory effect in vivo, whereas THC alone does not reduce pro-inflammatory or increase anti-inflammatory cytokines. It is anticipated that this information could be used to inform human clinical trials of cannabinoids, focusing on CBD and CBG to reduce inflammation across a range of pathophysiological processes.
Introduction: Some cannabinoids have been identified as anti-inflammatory agents; however, their potential therapeutic or prophylactic applications remain controversial. The aim of this systematic review was to provide a timely and comprehensive insight into cannabinoid-mediated pro- and anti-inflammatory cytokine responses in preclinical in vivo studies. Methods and Materials: A systematic search was conducted using PubMed, Web of Science, EMBASE, and Scopus. Eligible studies where cannabinoids had been evaluated for their effect on inflammation in animal models were included in the analysis. Data were extracted from 26 of 4247 eligible full text articles, and risk of bias was assessed using the SYstematic Review Center for Laboratory animal Experimentation (SYRCLE) tool. Studies examined cannabidiol (CBD; n=20); cannabigerol (CBG; n=1); delta 9-tetrahydrocannabinol (THC; n=2); THC and CBD separately (n=1); and THC and CBD in combination (n=2). Results: Tumor necrosis factor alpha, interleukin (IL)-1β, IL-6, and interferon gamma were the most commonly studied pro-inflammatory cytokines and their levels were consistently reduced after treatment with CBD, CBG, or CBD+THC, but not with THC alone. The association between cannabinoid-induced anti-inflammatory response and disease severity was examined. In 22 studies where CBD, CBG, or CBD in combination with THC were administered, a reduction in the levels of at least one inflammatory cytokine was observed, and in 24 studies, some improvements in disease or disability were apparent. THC alone did not reduce pro-inflammatory cytokine levels (n=3), but resulted in improvements in neuropathic pain in one study. Conclusions: This review shows that CBD, CBG, and CBD+THC combination exert a predominantly anti-inflammatory effect in vivo, whereas THC alone does not reduce pro-inflammatory or increase anti-inflammatory cytokines. It is anticipated that this information could be used to inform human clinical trials of cannabinoids, focusing on CBD and CBG to reduce inflammation across a range of pathophysiological processes.
Authors: Aitor G Granja; Francisco Carrillo-Salinas; Alberto Pagani; María Gómez-Cañas; Roberto Negri; Carmen Navarrete; Miriam Mecha; Leyre Mestre; Bend L Fiebich; Irene Cantarero; Marco A Calzado; Maria L Bellido; Javier Fernandez-Ruiz; Giovanni Appendino; Carmen Guaza; Eduardo Muñoz Journal: J Neuroimmune Pharmacol Date: 2012-09-14 Impact factor: 4.147
Authors: Penny F Whiting; Robert F Wolff; Sohan Deshpande; Marcello Di Nisio; Steven Duffy; Adrian V Hernandez; J Christiaan Keurentjes; Shona Lang; Kate Misso; Steve Ryder; Simone Schmidlkofer; Marie Westwood; Jos Kleijnen Journal: JAMA Date: 2015 Jun 23-30 Impact factor: 56.272
Authors: A Ribeiro; V I Almeida; C Costola-de-Souza; V Ferraz-de-Paula; M L Pinheiro; L B Vitoretti; J A Gimenes-Junior; A T Akamine; J A Crippa; W Tavares-de-Lima; J Palermo-Neto Journal: Immunopharmacol Immunotoxicol Date: 2014-10-30 Impact factor: 2.730
Authors: Francieli Vuolo; Soraia C Abreu; Monique Michels; Débora G Xisto; Natália G Blanco; Jaime Ec Hallak; Antonio W Zuardi; José A Crippa; Cardine Reis; Marina Bahl; Emílio Pizzichinni; Rosemeri Maurici; Marcia M M Pizzichinni; Patricia R M Rocco; Felipe Dal-Pizzol Journal: Eur J Pharmacol Date: 2018-11-24 Impact factor: 4.432
Authors: Stefan J Borgwardt; Paul Allen; Sagnik Bhattacharyya; Paolo Fusar-Poli; Jose A Crippa; Marc L Seal; Valter Fraccaro; Zerrin Atakan; Rocio Martin-Santos; Colin O'Carroll; Katya Rubia; Philip K McGuire Journal: Biol Psychiatry Date: 2008-06-27 Impact factor: 13.382
Authors: Chris D Verrico; Shonda Wesson; Vanaja Konduri; Colby J Hofferek; Jonathan Vazquez-Perez; Emek Blair; Kenneth Dunner; Pedram Salimpour; William K Decker; Matthew M Halpert Journal: Pain Date: 2020-09-01 Impact factor: 7.926
Authors: Anna Suleri; Elisabet Blok; Melisa Durkut; Anna-Sophie Rommel; Lot de Witte; Vincent Jaddoe; Veerle Bergink; Tonya White Journal: Brain Behav Immun Date: 2022-04-02 Impact factor: 19.227
Authors: Szymon Hryhorowicz; Marta Kaczmarek-Ryś; Aleksandra Zielińska; Rodney J Scott; Ryszard Słomski; Andrzej Pławski Journal: Front Immunol Date: 2021-12-22 Impact factor: 7.561
Authors: Peter Gál; Jan Brábek; Michal Holub; Milan Jakubek; Aleksi Šedo; Lukáš Lacina; Karolína Strnadová; Petr Dubový; Helena Hornychová; Aleš Ryška; Karel Smetana Journal: Histochem Cell Biol Date: 2022-07-22 Impact factor: 2.531
Authors: Cristian Scheau; Constantin Caruntu; Ioana Anca Badarau; Andreea-Elena Scheau; Anca Oana Docea; Daniela Calina; Ana Caruntu Journal: J Pers Med Date: 2021-05-31